Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
EpiVax (company)

EpiVax (company)

A computational immunology and vaccine development company based in Providence, Rhode Island. It was founded in 1998.

EpiVax is a Rhode Island-based immunology company dedicated to applying its tools (in-silico, in-vitro, and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines.The company has various offerings, such as vaccine services, immunogenicity assessment, deimmunizaiton, laboratory services, and pipeline services.

COVID-19

The company has been developing a peptide-based, epitope-driven vaccine candidate for healthcare workers who are working during the COVID-19 pandemic. It has partnered with the GAIA Vaccine Foundation (GVF). The two entities are crowd-sourcing the funds and have pledged to make a free license available to developing countries who qualify for it.

The company's research is being conducted in conjunction with researchers at the University of Georgia's Center for Vaccines and Immunology.

Timeline

September 12, 2016
EpiVax raises a $600,000 grant from National Institutes of Health.
November 1, 2012
EpiVax raises a $55,000 grant from GBS/CIDP Foundation International.
September 5, 2012
EpiVax raises a $300,000 grant from National Institutes of Health.
April 9, 2012
EpiVax raises a $1,500,000 grant from National Institutes of Health.
January 25, 2011
EpiVax raises a $458,000 grant from National Institutes of Health.
November 26, 2008
EpiVax raises a $390,000 grant from National Institutes of Health.
July 8, 2008
EpiVax raises a $600,000 grant from National Institutes of Health.
February 28, 2007
EpiVax raises a $368,000 grant from National Institutes of Health.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

EpiVax Accelerates COVID-19 Vaccine Development with UGA's Center for Vaccines and Immunology

Web

March 4, 2020

EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countrie

Ulrich Martin

Web

Executive Suite 10/11/2015: EpiVax CEO Annie De Groot

Web

October 8, 2015

News

Title
Author
Date
Publisher
Description
July 6, 2021
BioSpace
Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax - read this article along with other careers information, tips and advice on BioSpace
EpiVax Inc.
May 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. (« EpiVax ») annonce la publication de « Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for...
EpiVax Inc.
May 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") hat die Veröffentlichung der Studie "Hoch konservierte, nicht menschenähnliche und kreuzreaktive SARS-CoV-2...
EpiVax Inc.
May 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") anuncia la publicación "Epítopos de células T del SARS-CoV-2 altamente conservados, no similares a los humanos y con...
EpiVax Inc.
April 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. (« EpiVax ») annonce la publication « Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs » dans...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.